The GeneNovate Investors' Day is a networking event that brings together scientifically and translationally oriented project teams, international startups, investors, and experts from academia, industry, and policy-making.
The goal is to discover the latest developments in gene and cell therapies and identify promising investment opportunities.
Discussions will focus on the latest scientific developments, emerging technologies, and strategies for accelerating the translation of innovative therapies into clinical applications. The programme will also feature 20 pitches and showcases, highlighting novel solutions such as platform technologies in gene and cell therapy from international startups.
For more information on the programme please visit this Website.
Gene and cell-based therapies, also known as Advanced Therapy Medicinal Products (ATMPs), are gaining global significance. Patients with rare diseases—at least 4 million in Germany alone—and those with previously untreatable cancers stand to benefit greatly from these therapies. Technological advancements, including the expanded use of artificial intelligence, are further driving this field forward.
As of December 2024, sixteen gene therapies and one cell therapy are approved in Europe, with the number of clinical trials worldwide continuously increasing. The market for these innovative therapies is expected to experience groundbreaking developments by 2026, with projected revenues reaching up to €27.9 billion.
Recognizing this potential, the German government has established a National Strategy for Gene- and Cell-Based Therapies, defining concrete measures to improve research and development, regulatory frameworks, and manufacturing conditions.
